PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.91%
Revenue growth of 11.91% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
229.93%
Gross profit growth of 229.93% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
-19.65%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 2.87%. Seth Klarman would check if external or internal factors caused the decline.
-19.65%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.28%. Seth Klarman would check if structural or cyclical issues are at play.
495.53%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.39%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
479.36%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.61%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
486.45%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.53%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-128.34%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -18.01%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-5.43%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is -0.14%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
231.50%
3Y CAGR of 231.50% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-2712.91%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-106697.14%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-432.17%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
2364.45%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.55% over a decade. Joel Greenblatt might see a standout compounder of earnings.
4240.51%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 22.26%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
1153.04%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 5.83%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
5805.96%
Equity/share CAGR of 5805.96% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
7110.93%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 36.76%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
2546.66%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 15.17%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
515.88%
AR growth of 515.88% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
55.77%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
22.83%
Asset growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.52%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
23.55%
Positive BV/share change while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
78.69%
Debt growth of 78.69% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
25.44%
We slightly increase R&D while Drug Manufacturers - Specialty & Generic is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
5.88%
SG&A growth of 5.88% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.